Hemab Therapeutics Holdings, Inc. (COAG): who owns it and who trades it
As of Nov 16, 2026, COAG insiders reported 16 purchases worth $55.5M in the last 12 months. The largest buyer was Rajeev M. Shah (Director), with $52.2M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Hemab Therapeutics Holdings
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns COAG
56 funds and institutions reported COAG shares worth $1.3B at the end of Q2 2026, about 78% of the company. The largest holder is Ra Capital Management, L.P. with 16.7%.
Funds and institutions (13F) 78%Everyone else 22%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 7.81M | 16.72% | $287M | – |
| Novo Holdings A/s | 4.18M | 8.95% | $154M | – |
| FMR LLC (Fidelity) | 3.70M | 7.92% | $136M | – |
| Capital International Investors | 3.60M | 7.72% | $132M | – |
| Deep Track Capital, LP | 3.60M | 7.71% | $132M | – |
| Siren, L.L.C. | 2.09M | 4.47% | $76.6M | – |
| Avoro Capital Advisors LLC | 1.93M | 4.12% | $70.7M | – |
| Bain Capital Life Sciences Investors, LLC | 1.65M | 3.53% | $60.6M | – |
| JPMorgan Chase & Co | 1.15M | 2.47% | $42.3M | – |
| Vanguard Capital Management LLC | 780,758 | 1.67% | $28.7M | – |
| T. Rowe Price Associates | 746,040 | 1.60% | $27.4M | – |
| Driehaus Capital Management LLC | 715,791 | 1.53% | $26.3M | – |
| Rock Springs Capital Management LP | 575,432 | 1.23% | $21.1M | – |
| Bellevue Group AG | 550,000 | 1.18% | $20.2M | – |
| Citadel Advisors LLC | 523,450 | 1.12% | $19.2M | – |
| BlackRock, Inc. | 283,833 | 0.61% | $10.4M | – |
| Deerfield Management Company, L.P. | 275,000 | 0.59% | $10.1M | – |
| ExodusPoint Capital Management, LP | 218,287 | 0.47% | $8M | – |
| Geode Capital Management, LLC | 211,798 | 0.45% | $7.8M | – |
| Braidwell LP | 160,000 | 0.34% | $5.9M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, COAG insiders reported $55.5M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Purchase | 61,523 | $24.98 | $1.5M | Form 4 |
| Jun 15, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Purchase | 6,146 | $24.89 | $153K | Form 4 |
| May 20, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Purchase | 996 | $24.94 | $24.8K | Form 4 |
| May 19, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Purchase | 3,802 | $24.97 | $94.9K | Form 4 |
| May 12, 2026 | Peter Kolchinsky +3 | 10% owner | Purchase | 6,387 | $24.90 | $159K | Form 4 |
| May 11, 2026 | RA Capital Healthcare Fund LP +3 | 10% owner | Purchase | 25,720 | $25.00 | $643K | Form 4 |
| May 11, 2026 | RA Capital Healthcare Fund LP +3 | 10% owner | Purchase | 14,149 | $24.47 | $346K | Form 4 |
| May 8, 2026 | RA Capital Healthcare Fund LP +3 | 10% owner | Purchase | 1,483 | $24.98 | $37K | Form 4 |
| May 7, 2026 | RA Capital Healthcare Fund LP +3 | 10% owner | Purchase | 1,985 | $24.95 | $49.5K | Form 4 |
| May 7, 2026 | RA Capital Healthcare Fund LP +3 | 10% owner | Purchase | 7,921 | $24.34 | $193K | Form 4 |
| May 6, 2026 | Rajeev M. Shah +5 | Director | Purchase | 53,407 | $24.83 | $1.3M | Form 4 |
| May 6, 2026 | Rajeev M. Shah +5 | Director | Purchase | 14,611 | $23.77 | $347K | Form 4 |
| May 5, 2026 | Rajeev M. Shah +5 | Director | Purchase | 10,268 | $25.00 | $257K | Form 4 |
| May 5, 2026 | Rajeev M. Shah +5 | Director | Purchase | 87,143 | $24.59 | $2.1M | Form 4 |
| May 4, 2026 | Rajeev M. Shah +5 | Director | Purchase | 133,750 | $18.00 | $2.4M | Form 4 |
| May 4, 2026 | Rajeev M. Shah +5 | Director | Purchase | 2.54M | $18.00 | $45.7M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Rajeev M. Shah | Director, 10% owner | $52.2M | – | May 6, 2026 |
| Ra Capital Management, L.P. | 10% owner | $1.8M | – | Jun 16, 2026 |
| RA Capital Healthcare Fund LP | 10% owner | $1.3M | – | May 11, 2026 |
| Peter Kolchinsky | 10% owner | $159K | – | May 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
COAG short interest
Moderate short interest. 7.1% of COAG shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 336%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.31M COAG shares were sold short, 7.1% of the shares outstanding, up 4.6% from the report before. At the average daily volume of 451,955 shares, buying them all back would take about 7.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.31M | 7.07% | +5% | 451,955 | 7.3 |
| Oct 15, 2026 | 3.16M | 6.77% | -7% | 404,790 | 7.8 |
| Sep 30, 2026 | 3.39M | 7.26% | +28% | 811,205 | 4.2 |
| Sep 15, 2026 | 2.64M | 5.65% | +25% | 350,112 | 7.5 |
| Aug 31, 2026 | 2.11M | 4.51% | +4% | 349,480 | 6.0 |
| Aug 14, 2026 | 2.03M | 4.35% | -0% | 330,066 | 6.2 |
| Jul 31, 2026 | 2.04M | 4.36% | +23% | 479,211 | 4.2 |
| Jul 15, 2026 | 1.66M | 3.55% | -3% | 311,224 | 5.3 |
| Jun 30, 2026 | 1.71M | 3.67% | +27% | 423,786 | 4.0 |
| Jun 15, 2026 | 1.35M | 2.90% | +32% | 179,441 | 7.5 |
| May 29, 2026 | 1.03M | 2.20% | +35% | 158,083 | 6.5 |
| May 15, 2026 | 758,697 | 1.62% | – | 622,622 | 1.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Hemab Therapeutics Holdings company events
Hemab Therapeutics Holdings filed 6 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Sep 24, 2026LeadershipUpon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of Hemab Therapeutics Holdings, Inc., the Board elected Keli Walbert to serve as a member of the Board, effective immediately. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- May 21, 2026ResultsReleased financial results. Filing
- May 11, 2026LeadershipLaura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. of her decision to resign as a member of the Company’s board of directors, effective immediately. Filing
- May 4, 2026AnnouncementThe Company completed its IPO of 19,262,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,512,500 additional shares of common stock, at a public offering price of $18.00 per share. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold COAG
4 of the 50 well-known investors we track reported holding COAG in their latest 13F filing. The largest position is Ken Griffin's, worth $2.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 90,412 | $2.8M | 0.0% | -83% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 67,542 | $2.1M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 11,695 | $361K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 7,458 | $230K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named COAG in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 6, 2026 | FMR LLC | 13G/A | 10.4% |
| Nov 6, 2026 | FMR LLC | 13G/A | 10.4% |
Questions about Hemab Therapeutics Holdings, Inc. (COAG) stock
Who owns the most COAG stock?
The largest reported owner of Hemab Therapeutics Holdings, Inc. (COAG) is Ra Capital Management, L.P., with 16.7% of the company. In total, 56 funds and institutions reported holding COAG at the end of Q2 2026, together about 78% of the shares. See the largest owners.
Are COAG insiders buying or selling?
In the last 12 months, COAG insiders reported 16 open-market purchases worth $55.5M and no sales. The latest trade was on Jun 16, 2026. See every trade.
What is the short interest in COAG?
As of Oct 30, 2026, 3.31M COAG shares were sold short, 7.1% of the shares outstanding, up 4.6% from the report before. At the average daily volume of 451,955 shares, buying them all back would take about 7.3 trading days (days to cover). See the history.
Which famous investors hold COAG?
4 of the 50 well-known investors we track reported COAG in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $2.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.